Mechanism of Serum PRL in the Development of MAFLD

Shen Qu

Status: Enrolling

Conditions: Fatty Liver, Nonalcoholic; Type2 Diabetes; Liver Fibrosis

Treatments: Other: non-invasive method, Fibroscan

Study type: Observational

Funder types: Other

Identifiers

NCT05525884

PRL

Details and patient eligibility

About

Metabolic associated fatty liver disease (MAFLD) has currently reached a worldwide epidemic. Serum PRL levels within or outside physiological range have been found to affect metabolic homeostasis differently. However, the relationship between serum PRL and MAFLD among diabetic patients is unclear. The investigators aimed to explore the association between serum PRL and the risk of MAFLD in patients with type 2 diabetes (T2DM).

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• aged 18~65 years old,
• underwent the laboratory tests, hepatic ultrasonography, and valid transient elastography (FibroScan) examination

Exclusion criteria

• other known chronic liver diseases, such as chronic hepatitis B or C, autoimmune hepatitis, and haemochromatosis
• pre-existing active cancer, renal dysfunction, severe liver dysfunction, congestive heart failure or free abdominal fluid
• history of hyperthyroidism or hypothyroidism, pituitary diseases, and other types of diabetes
• significant alcohol consumption
• pregnancy
• receiving any therapeutic methods that could lead to liver steatosis or fibrosis, influence the glucolipid metabolism, or PRL levels, such as lipid-lowering, and PRL-lowering agents (bromocriptine) within 6 months prior to this study.

Trial design

1,000 participants in 3 patient groups

MAFLD and Non-MAFLD

Treatment:

Other: non-invasive method, Fibroscan

Steatosis and Non-Steatosis

Treatment:

Other: non-invasive method, Fibroscan

Fibrosis and Non-Fibrosis

Treatment:

Other: non-invasive method, Fibroscan